Evaluation of Macular Edema After AcF Implant's Injection, 1 Month After the Last DXM Implant

Launched by NANTES UNIVERSITY HOSPITAL · Aug 10, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a special eye injection called a fluocinolone acetonide (AcF) implant, which is given to patients with macular edema—swelling in the retina—after they have already received another treatment called a dexamethasone (DXM) implant. The goal is to see how well the AcF implant works over a longer period and to check for any potential side effects, especially concerning eye pressure, which can be a concern with long-term steroid use. The AcF implant is designed to release medication for 2 to 3 years, whereas the DXM implant lasts only 3 to 6 months.

To be eligible for this trial, participants must be at least 18 years old and have already received an AcF injection one month after a DXM injection for diabetic or uveitic macular edema. Participants will be monitored for three years to gather important information about their vision and eye health. This study aims to provide better insights into how well this treatment works and its safety over time, helping doctors make informed decisions for patients with this condition. If you’re considering joining the trial, remember that your medical data will be used for research, but only if you agree to it.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient (Male, Female)°≥ 18 years old
• • Having received an AcF injection 1 month after a DXM injection
• • For diabetic macular edema or uveitic macular edema
• Exclusion Criteria:
• • Patient's refusal to allow his or her medical data to be used for research purposes